Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 11 September, 2019

Citadel Group

Form 8.3 - Allergan plc

RNS Number : 9670L
Citadel Group
11 September 2019
 



















 

Ap 19

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.         KEY INFORMATION





















Name of person dealing (Note 1)

Citadel Group

Company dealt in

ALLERGAN PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common Stock ISIN IE00BY9D5467

Date of dealing

10 September, 2019



















2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security

                    dealt in (Note 3)






Long

Short

Common Stock  ISIN  IE00BY9D5467

Number        (%)

Number      (%)

(1) Relevant securities

1,983,201 (0.60%)

178 (0.00%)

(2) Derivatives (other than options)

4,108,576 (1.25%)

0 (0.00%)

(3) Options and agreements to purchase/sell

0 (0.00%)

0 (0.00%)

Total

6,091,777(1.86%)

178 (0.00%)





















 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)



















Long

Short


Number        (%)

Number      (%)

(1) Relevant securities



(2) Derivatives (other than options)



(3) Options and agreements to purchase/sell



Total


























Ap 20

























1.         DEALINGS (Note 4)

 

(a)        Purchases and sales







































(b)        Derivatives transactions (other than options transactions)


















Product name,

e.g. CFD

Common Stock ISIN IE00BY9D5467

Nature of transaction

(Note 6)

 

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

CFD

Opening long position

20,000

162.901583  USD

CFD

Reducing long position

-61,061

163.886819  USD

CFD

Reducing long position

-18,546

163.918128  USD






















(c)        Options transactions in respect of existing relevant securities

 

(i)         Writing, selling, purchasing or varying






















Product name, e.g. call option

Writing, selling, purchasing,

varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type,e.g. American, European etc.

Expiry date

Option money paid/ received per unit (Note 5)


























(ii)        Exercising




















Product name,

e.g. call option

Number of securities

Exercise price per unit

(Note 5)



























(d)        Other dealings (including transactions in respect of new securities) (Note 4)



























 



















Ap 21

















2.         OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 
















Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated

None














Is a Supplemental Form 8 attached? (Note 9)


NO

















 Date of disclosure:

11 September, 2019

 Contact name:

Katie Bonds

 Telephone number:

020 7645 9700

If a connected EFM, name of offeree/offeror with which connected

n/a

If a connected EFM, state nature of connection (Note 10)

n/a



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEGCGDCGGBBGCB

a d v e r t i s e m e n t